hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:北京哪家癫痫医院排名好,成本低
下一页:癫痫患者手术评估新型工具
- 2022-04-25一文掌握癫痫病患宝典
- 2022-04-20哪些抗菌药物可诱发发作?
- 2022-04-13癫痫治愈费用
- 2022-04-12癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 2022-04-11英国竞争监管机构指控辉瑞癫痫药品价格过高
- 2022-04-11癫痫治疗障碍仍难以克服
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 癫痫治疗障碍仍难以克服
- 2016AAN:神经专家发表了有前途的专业见解
- FDA批准Aptiom用于治疗患者癫痫发作
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 抗癫痫药物预防新发癫痫:任重而道远
- 心理百科:春节期间小心疾病
- 美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 癫痫患者手术评估新型工具
- 2013国际抗癫痫联合会抗癫痫药用指南
- 北京哪家癫痫医院排名好,成本低
- 心率多少正常 如何保持正常心率不变
- 2015 神经系统疾病诊疗进展
- 月经期间要注意 有些药物和食物不能食用
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 20首款慢性肾脏病治疗药物Forxiga获得NICE推荐
- 控制癫痫患者再次抽搐,不包括可选药物?
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 羊角风有什么症状?
- 综述:癫痫持续状态诊治最新进展
- UCB的Vimpat癫痫新适应症在美国获批
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 三庚酸酯可治疗1型转运体缺陷综合征
- 癫痫会遗传吗 癫痫的治疗方法
- 癫痫病皮肤病费用
- 小儿良性癫痫病有什么副作用
- 孩童癫痫病怎么治疗最彻底
- 天使科普:家长必看!儿童哮喘怎么治?选对疗法是关键
- 世界抑郁症日 | 科学防治 规范诊疗 告别抑郁症
- 癫痫病的头痛症状有哪些
- 未满癫痫病病因有哪些
- 阿尔茨海默病或是人类特有疾病,同神经元及神经环路活性诱发相关
- 抗病毒方案修订对抗病毒结果和费用的影响
- 怎么用药癫痫病
- 癫痫病能治愈吗,先简要了解情况?
- 癫痫病的治疗法方法有哪些常用方式
- 人类记忆究竟如何形成及提取?迄今最清晰证据显现出!